MDGL Logo

Madrigal Pharmaceuticals, Inc. (MDGL) 

NASDAQ
Market Cap
$7.35B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
3 of 776
Rank in Industry
3 of 433

Largest Insider Buys in Sector

MDGL Stock Price History Chart

MDGL Stock Performance

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with …

Insider Activity of Madrigal Pharmaceuticals, Inc.

Over the last 12 months, insiders at Madrigal Pharmaceuticals, Inc. have bought $77.75M and sold $85.7M worth of Madrigal Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Madrigal Pharmaceuticals, Inc. have bought $77.75M and sold $122.85M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $1.17B.

The last purchase of 20,633 shares for transaction amount of $4.71M was made by BAKER BROS. ADVISORS LP (director) on 2023‑12‑14.

List of Insider Buy and Sell Transactions, Madrigal Pharmaceuticals, Inc.

2024-11-01Saledirector
5,000
0.0217%
$300.94$1.5M+3.67%
2024-09-09SalePresident and CEO
6,363
0.0299%
$243.83$1.55M-9.54%
2024-06-14SaleSenior VP, Chief Pharma Dev.
1,900
0.0085%
$280.00$532,000-12.14%
2024-06-12SaleSenior VP, Chief Pharma Dev.
2,000
0.0092%
$285.00$570,000-14.17%
2024-05-21SaleSenior VP, Chief Pharma Dev.
1,036
0.0046%
$231.34$239,668+0.53%
2024-05-14Saledirector
22,489
0.1065%
$212.88$4.79M+15.07%
2024-04-08SalePres., R&D, and CMO
2,676
0.0126%
$245.99$658,258-5.16%
2024-04-08Saledirector
26,270
0.1239%
$246.19$6.47M-5.16%
2024-04-05SalePres., R&D, and CMO
22,228
0.1058%
$242.84$5.4M-2.92%
2024-04-05SalePres., R&D, and CMO
27,506
0.1312%
$243.36$6.69M-2.92%
2024-04-05Saledirector
27,613
0.1317%
$243.40$6.72M-2.92%
2024-04-04SalePres., R&D, and CMO
13,339
0.0636%
$241.81$3.23M-2.22%
2024-04-04SalePres., R&D, and CMO
18,537
0.0888%
$242.91$4.5M-2.22%
2024-04-04Saledirector
18,710
0.0897%
$242.96$4.55M-2.22%
2024-04-03SalePres., R&D, and CMO
6,839
0.0342%
$244.24$1.67M-3.66%
2024-04-03SalePres., R&D, and CMO
27,845
0.1399%
$245.14$6.83M-3.66%
2024-04-03Saledirector
27,407
0.1377%
$245.12$6.72M-3.66%
2024-04-02Saledirector
10,912
0.0548%
$244.51$2.67M-3.31%
2024-04-02Saledirector
11,212
0.0563%
$244.49$2.74M-3.31%
2024-04-01Saledirector
11,000
0.0557%
$257.49$2.83M-7.54%

Insider Historical Profitability

39.49%
BAKER BROS. ADVISORS LPdirector
1793403
8.2227%
$337.1790
CRAVES FRED Bdirector
413362
1.8953%
$337.1716<0.0001%
FRIEDMAN PAUL Adirector
185735
0.8516%
$337.1725<0.0001%
Levy Richard Sdirector
11012
0.0505%
$337.1733+602.61%
Bahcall Safi RPresident and CEO
2053135
9.4136%
$337.17120+16.52%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Janus Henderson$694.53M12.212.6M-10.36%-$80.3M0.35
Baker Bros Advisors LP$526.01M9.241.97M0%+$03.78
Avoro Capital Advisors Llc$519.24M9.121.94M+2.94%+$14.84M6.22
Paulson & Co.$474M8.331.77M+60.53%+$178.72M32.75
The Vanguard Group$445.64M7.831.67M+5.97%+$25.12M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.